Long-term study finds faster breast cancer radiation treatment as effective as long course

December 05, 2019

HAMILTON, ON (December 5, 2019) - A shorter course of higher-dose radiation treatment to part of the breast is showing promise in women with early-stage breast cancer who undergo breast conserving surgery, says a study led by Hamilton researchers.

Accelerated partial breast irradiation (APBI) sees larger doses of radiation delivered to parts of the breast affected by cancer. This treatment takes place in one week or less, further reducing length of treatment from the standard treatment of three to five weeks.

The multi-centre trial shows similar recurrence rates of breast cancer in patients treated by external beam APBI over the course one week compared to whole breast radiation delivered over three to five weeks.

The study data was published today in The Lancet.

"We wanted to do a study to see if we could shorten treatment as three to five weeks is not ideal for patients," said first author Timothy Whelan, professor of oncology at McMaster University and a radiation oncologist of Hamilton Health Sciences. He holds a Canada Research Chair in Breast Cancer Research.

The randomized controlled trial, called RAPID, occurred between 2006 and 2011 in 33 cancer centres across Canada, Australia and New Zealand.

The 2,135 patients were women aged 40 or older with ductal carcinoma or node-negative breast cancer which had been treated by breast conserving surgery.

Approximately half of the patients were randomly assigned whole breast radiation, delivered once per day over three to five weeks. The other half received external beam APBI, considered to be the least invasive approach to partial breast irradiation, which was given twice a day over five to eight days.

The study was long-term, with a median followup of 8.6 years. At eight years, the risk of cancer recurrence in the breast was very low and similar for the two groups. For patients treated with APBI the risk was three per cent and for patients treated with whole breast radiation the risk was 2.8 per cent.

"The results after more than eight years are exciting because they showed, with long followup, that the risk of cancer coming back in the breast was reduced with APBI to the same degree as whole breast radiation," Whelan said.

However, his research team was surprised to find that although less early toxicity within three months of treatment was observed with APBI, the twice-daily regimen was likely associated with higher late toxic effects and worse cosmetic outcomes. This included increased small blood vessels visible on the skin, and thickening of breast tissue related to radiation.

"About 13 per cent of patients who had whole breast radiation had moderate toxicity, compared to 32 per cent for those who had APBI," said Whelan. "As well, about 16 per cent more women treated with accelerated partial breast treatment didn't feel their breast looked as good.

"Based on this, it is difficult to recommend the twice per day regimen at this time."

Whelan and his team are now conducting a clinical trial to examine whether once per day APBI with more time between treatments will have better outcomes.

"We're looking at external beam accelerated partial breast irradiation with five treatments, but only once per day rather than twice," he said. "The early results are very promising because we're not seeing that toxicity and our goal is to examine that further."
The study was funded by the Canadian Institutes of Health Research and the Canadian Breast Cancer Research Alliance. The trial was conducted by the Ontario Clinical Oncology Group of McMaster and Hamilton Health Sciences.

Editors: A photo of Timothy Whelan is attached.

Photo caption: Timothy Whelan is a professor of oncology at McMaster University and a radiation oncologist at the Juravinski Cancer Centre of Hamilton Health Sciences. He holds a Canada Research Chair in Breast Cancer Research. Photo courtesy McMaster University

For more information or to arrange an interview, please contact:

Veronica McGuire
Media Relations
McMaster University
905-525-9140, ext. 22169

Roxanne Torbiak
Public Relations
Hamilton Health Sciences

McMaster University

Related Breast Cancer Articles from Brightsurf:

Oncotarget: IGF2 expression in breast cancer tumors and in breast cancer cells
The Oncotarget authors propose that methylation of DVDMR represents a novel epigenetic biomarker that determines the levels of IGF2 protein expression in breast cancer.

Breast cancer: AI predicts which pre-malignant breast lesions will progress to advanced cancer
New research at Case Western Reserve University in Cleveland, Ohio, could help better determine which patients diagnosed with the pre-malignant breast cancer commonly as stage 0 are likely to progress to invasive breast cancer and therefore might benefit from additional therapy over and above surgery alone.

Partial breast irradiation effective treatment option for low-risk breast cancer
Partial breast irradiation produces similar long-term survival rates and risk for recurrence compared with whole breast irradiation for many women with low-risk, early stage breast cancer, according to new clinical data from a national clinical trial involving researchers from The Ohio State University Comprehensive Cancer Center - Arthur G.

Breast screening linked to 60 per cent lower risk of breast cancer death in first 10 years
Women who take part in breast screening have a significantly greater benefit from treatments than those who are not screened, according to a study of more than 50,000 women.

More clues revealed in link between normal breast changes and invasive breast cancer
A research team, led by investigators from Georgetown Lombardi Comprehensive Cancer Center, details how a natural and dramatic process -- changes in mammary glands to accommodate breastfeeding -- uses a molecular process believed to contribute to survival of pre-malignant breast cells.

Breast tissue tumor suppressor PTEN: A potential Achilles heel for breast cancer cells
A highly collaborative team of researchers at the Medical University of South Carolina and Ohio State University report in Nature Communications that they have identified a novel pathway for connective tissue PTEN in breast cancer cell response to radiotherapy.

Computers equal radiologists in assessing breast density and associated breast cancer risk
Automated breast-density evaluation was just as accurate in predicting women's risk of breast cancer, found and not found by mammography, as subjective evaluation done by radiologists, in a study led by researchers at UC San Francisco and Mayo Clinic.

Blood test can effectively rule out breast cancer, regardless of breast density
A new study published in PLOS ONE demonstrates that Videssa® Breast, a multi-protein biomarker blood test for breast cancer, is unaffected by breast density and can reliably rule out breast cancer in women with both dense and non-dense breast tissue.

Study shows influence of surgeons on likelihood of removal of healthy breast after breast cancer dia
Attending surgeons can have a strong influence on whether a patient undergoes contralateral prophylactic mastectomy after a diagnosis of breast cancer, according to a study published by JAMA Surgery.

Young breast cancer patients undergoing breast conserving surgery see improved prognosis
A new analysis indicates that breast cancer prognoses have improved over time in young women treated with breast conserving surgery.

Read More: Breast Cancer News and Breast Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.